Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Nanostring human miRNA panel: exosome fraction from peripheral blood of trauma patients versus healthy

ABSTRACT: Nanostring human miRNA panel: exosome fraction from peripheral blood of trauma patients versus healthy

PROVIDER: PRJNA1018565 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Nanostring human miRNA panel: exosome fraction from peripheral blood of trauma patients versus healthy

Project description:827 human miRNA standard human panel Plasma derived extracellular vesicles (EV)/exosomes can serve as markers of cell damage/disease but can also have therapeutic utility depending on the nature of their cargo, such as miRNA. Currently there are challenges and lack of innovations regarding early diagnosis and therapeutic options within different aspects of management of trauma patients. We characterized the miRNA cargo of exosomes purified from trauma patients, and compared it to those from healthy participants. Methods Plasma was collected from a prospective, cohort study of trauma patients (n = 15; 7 males, 8 females) with hip and/or femur fractures and an injury severity score (ISS) ≥ 15; elective total hip arthroplasty (THA) patients (n = 8; 4 males, 4 females) served as operative controls. Exosomes were isolated from plasma with the Invitrogen Total Exosome Isolation Kit and RNA was isolated using a miRNeasy Mini Kit. Direct quantification of miRNA copies was performed by NanoString Technologies on a human miRNA gene panel and analyzed with nSolver Results Trauma plasma-derived exosomes had 60 miRNA that were significantly downregulated and 3 miR upregulated when compared to THA (p<0.05). Thirteen miR have a direct role in hematopoiesis regulation, including miR-223 and miR-451a. Further, male trauma plasma-derived exosomes demonstrated downregulation of 150 miR compared to male THA (p<0.05). While female trauma plasma-derived exosomes demonstrated downregulation of only four miR and upregulation of 2 miR compared to female THA (p<0.05). Conclusions Sex-specific differences in the miR from plasma-derived exosomes occurred following severe trauma. These miR changes in plasma-derived exosomes likely contribute to postinjury systemic inflammation, immune system dysregulation, and bone marrow dysfunction and may merit consideration as future potential therapeutic targets.

2024-04-03 | GSE243485 | GEO

Nanostring human miRNA panel: exosome fraction from peripheral blood of pancreatitis patients versus healthy

Project description:Nanostring human miRNA panel: exosome fraction from peripheral blood of pancreatitis patients versus healthy

| PRJNA725869 | ENA

Nanostring human miRNA panel: exosome fraction from peripheral blood of pancreatitis patients versus healthy

Project description:827 human miRNA standard human panel Plasma derived extracellular vesicles (EV)/exosomes can serve as markers of cell damage/disease but can also have therapeutic utility depending on the nature of their cargo, such as miRNA. Currently there are challenges and lack of innovations regarding early diagnosis and therapeutic options within different aspects of management of patients suffering from chronic pancreatitis (CP). Use of exosomes as biomarkers for pancreatic health, and/or or as adjuvant therapy would make a difference in management of these patients. To explore the feasibility of this approach, we characterized the miRNA cargo of exosomes purified from CP patients, and compared it to those from healthy participants. Methods: EVs were isolated from plasma of 15 CP patients and 10 healthy controls. Nanoparticle Tracking Analysis was used to determine frequency and size while NanoString technology was used to characterize the miRNA cargo. Relevant clinical parameters were correlated with these EV/exosome characteristics. Results: ~30 miRNA species were identified to have significantly (p<0.05) different expression in exosomes from individuals with CP compared to healthy individuals; ~40 miRNA were differentially expressed in exosomes from pre-diabetic versus non-diabetic CP patients. miR-579-3p, while exhibiting significantly lower (~16-fold) expression in exosomes from CP compared to healthy individuals and lower (~24-fold) in CP narcotic users compared to the less severe CP in non-users, is actually enriched (~32-fold) within exosomes in pre-diabetic CP patients compared to non-diabetic CP patients. A unique pattern was identified in female CP patients. Conclusions: These first of a kind data support the prospect of using a bioinformatics approach to assess pancreatic health, and their therapeutic potential in CP patients.

2021-04-29 | GSE173514 | GEO

nCounter NanoString Human Immunology V2 panel

Project description:nCounter NanoString Human Immunology V2 panel

| PRJNA751396 | ENA

Nanostring ncounter NHP Immunology V2 panel

Project description:Nanostring ncounter NHP Immunology V2 panel

| PRJNA792145 | ENA

Nanostring ncounter NHP Immunology V2 panel

Project description:The gene expression analysis of the RNA samples were analyzed with NanoString Non Human Primate immunology panel comprised of 754 immune related gene

2021-12-25 | GSE192584 | GEO

Nanostring analysis of medulloblastoma samples using the PanCancer Immune Profile Nanostring Panel

Project description:Nanostring analysis of medulloblastoma samples using the PanCancer Immune Profile Nanostring Panel

| PRJNA926966 | ENA

Human buffy coat gene expression, custom 250-plex Nanostring panel

Project description:Buffy coat PBMC RNA expression was tested using a custom Nanostring probe panel, to identify general immune and glucocorticoid receptor-associated immune genes. ClinicalTrials.gov Identifier: NCT00824941

2019-11-01 | GSE124549 | GEO

NanoString Human PC3 nCounter PanCancer IO 360 panel

Project description:NanoString Human PC3 nCounter PanCancer IO 360 panel

| PRJNA772256 | ENA

Nanostring nCounter Bovine Arrival BRD 60 Panel v1.0

Project description:Nanostring nCounter Bovine Arrival BRD 60 Panel v1.0

| PRJNA744165 | ENA